Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18563911 | 0.93 | TLR7 (0.86) | TLR7 | |
| SCHEMBL26257565 | 0.92 | TLR7 (0.75) | TLR7 | |
| SCHEMBL24007616 | 0.91 | TLR7 (0.84) | TLR7 | |
| SCHEMBL18584158 | 0.91 | TLR7 (0.83) | TLR7 | |
| SCHEMBL24233599 | 0.89 | TLR7 (0.79) | TLR7 | |
| SCHEMBL1146404 | 0.89 | TLR7 (0.82) | TLR7 | |
| SCHEMBL1146536 | 0.87 | TLR7 (0.83) | TLR7 | |
| SCHEMBL3128592 | 0.87 | TLR7 (0.82) | TLR7 | |
| SCHEMBL29391106 | 0.87 | TLR7 (1.00) | TLR7 | |
| SCHEMBL17417198 | 0.87 | TLR7 (1.00) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-07-18 | — | — | US | disclosed |
| US-20220251212-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-08-11 | — | — | US | disclosed |
| US-20220204641-A1 | ANTI-CD20 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-06-30 | — | — | US | disclosed |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-02-03 | — | — | US | disclosed |
| US-20210347911-A1 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-11-11 | — | — | US | disclosed |
| US-11130812-B2 | Anti PD-L1 conjugates for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-09-28 | — | — | US | disclosed |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-10-12 | — | — | US | disclosed |
| US-20170056391-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056391-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | TP53, MCL1, MSH2 | TLR7 1537/4885 |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | EGFR, ERBB3, ERBB2 | TLR7 2007/4885 |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | TLR7 883/4885 |
| US-20210347911-A1 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | ERBB2, EGFR, ERBB3 | TLR7 1770/4885 |
| US-11130812-B2 | Anti PD-L1 conjugates for treating tumors | CD274, PDCD1LG2, PDCD1 | TLR7 980/4885 |
| US-20220204641-A1 | ANTI-CD20 COMBINATIONS FOR TREATING TUMORS | CD209, CD68, CD47 | TLR7 1058/4885 |
| US-20220251212-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | PDCD1LG2, CD274, PDCD1 | TLR7 879/4885 |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | TLR7 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.